tbuckley/cabot-search huggingface dataset:
A program evaluation of best practice methods to assess integrated health needs for breast cancer survivors.
Authors: Katherine Ramsey Gilmore, Shamsha Damani, Rachel M King, Bonnie Nelson, Allica Austin, Sally Scroggs, Therese Bartholomew Bevers, Frances Ann Zandstra
Journal: Journal of Clinical Oncology (2014)

111 Background: A fundamental tenet of survivorship care is to identify and deliver a wide range of supportive care services. Survivors rely on clinicians to provide integrated care personalized to their own supportive care needs. Yet there is lack of evidence demonstrating which method is “best practice” when assessing survivor’s needs. The aim of our Plan-Do-Study-Act quality improvement project was to determine the best method to identify survivors’ supportive care needs and coordinate services. Methods: We used the appointment list of the Breast Survivorship Clinic to identify 114 adult survivors seen for their initial survivorship visit between January-March 2014. Survivors were asked to complete a questionnaire assessing their needs related to: 1) energy-balance, 2) complementary medicine, 3) lymphedema, 4) psychosocial concerns, 5) sexual health, and 6) tobacco use. Survivors were randomly assigned into 3 groups to identify the best method to assess their health care needs: 1) Mail, 2) Secure Electronic Messaging, and 3) Navigation Visit with Health Educator (HE). Questionnaires for the mail and electronic messaging groups were distributed before being seen in the clinic. Navigation participants completed the questionnaire during the visit with HE. Descriptive statistics were used to describe and compare group characteristics. Results: A total of 114 patients were randomized to complete the assessment by either mail (N=28), secured electronic message (N=50), or during the navigation visit (N=36). The in-person, navigation visit had the highest completion rate (78%) compared to secured message (22%), and mail (7%). An overwhelming majority of survivors’ in the navigation group (93%) indicated they had needs in in at least one of the 6 domains. The top two needs across all groups were nutrition and physical activity. Conclusions: This evaluation suggests the use of a health navigator to guide the survivor through the needs assessment was the most successful way to assess needs of long-term breast cancer survivors. Enhanced navigation during a cancer survivor’s visit can be used to tailor integrative health services, which can improve their well-being and mental health outcomes.
Abstract 4559: Sprouty2 differentially regulates signaling and phenotypic responses of glioblastoma cells to DNA damaging agents and receptor kinase inhibitors
Authors: Nisha G. Sosale, Sally Shin, Matthew J. Lazzara
Journal: Cancer Research (2016)

Abstract Key to improving glioblastoma patient survival is the exploration of the signaling mechanisms that regulate cellular response to approved and investigational therapeutics, including DNA damaging agents and targeted therapeutics such as EGFR and MET kinase inhibitors. Previous work from our group demonstrated that Sprouty2 (SPRY2) surprisingly acted more as a tumor promoter than tumor suppressor in glioblastoma cell lines and tumor xenografts, with SPRY2 knockdown reducing proliferation of human glioblastoma cells and antagonizing the growth of subcutaneous tumor xenografts in mice. We hypothesized here that these effects may result from a perturbation in the cell cycle and that such effects may augment cell cycle shifts induced by DNA damaging agents or kinase inhibitors. Flow cytometry measurements indicated shifts in DNA content distribution in glioblastoma cell lines consistent with cell cycle arrest in response to SPRY2 knockdown alone, and that these shifts were substantially augmented by carboplatin or to a lesser degree by a combination of EGFR and MET inhibitors, but not by temozolomide. Western blotting indicated that SPRY2 knockdown resulted in increased phosphorylation of Ataxia Telangiectasia Mutated (ATM), a kinase involved in the DNA damage response pathway, at a serine residue (1981) that regulates the dissociation of inactivate ATM homodimers into activated monomers. In response to carboplatin, but not the other therapeutics tested, a robust increase was observed in Checkpoint kinase 1 (CHK1) phosphorylation at serine 345, which has been reported to cause cell cycle arrest. This effect was further enhanced by SPRY2 knockdown, which may help explain why the largest cell cycle perturbations were observed in SPRY2-deficient cells treated with carboplatin. Increased phosphorylation of p38 was also observed in response to carboplatin or EGFR and MET inhibitors. This may have contributed to cell cycle arrest, but may also have cooperated with the inhibition of AKT phosphorylation that occurred only in response to EGFR and MET inhibition to drive cell death, an effect that was also augmented by SPRY2 knockdown. Overall, this work has identified a small network of SPRY2-regulated signaling processes that control phenotypic responses of glioblastoma cells to different clinically relevant therapeutics and provides motivation for further study of the role of SPRY2 in glioblastoma. Citation Format: Nisha G. Sosale, Sally Shin, Matthew J. Lazzara. Sprouty2 differentially regulates signaling and phenotypic responses of glioblastoma cells to DNA damaging agents and receptor kinase inhibitors. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4559.
Tracing the Cause of Abdominal Pain
Authors: Jennifer Nayor, Anand Vaidya, Amitabh Srivastava, Julian L. Seifter, Anna E. Rutherford
Journal: New England Journal of Medicine (2016)

A 19-year-old woman presented to the emergency department with abdominal pain in the right upper quadrant that had been progressively worsening for the past 2 days. She reported a 3-month history of intermittent abdominal pain that caused what she described as a "pressure-like" sensation. This pain was nonradiating and was unrelated to food intake or bowel movements. The pain was associated with . . .
Developmental Stage Specific B-Progenitor Expansion in Normal Fetal Bone Marrow Is Absent in Down Syndrome: Implications for Infant ALL
Authors: Anindita Roy, Georg Bohn, Katerina Goudevenou, Gillian Cowan, Neha Bhatnagar, David O'Connor, Oliver Tunstall, Jerry Chan, Phillip Bennett, Sailesh Kumar, Deena Iskander, Sarah Inglott, Binbin Liu, Philip Ancliff, Anastasios Karadimitris, Irene Roberts
Journal: Blood (2014)
Day 100 PET Scan Positivity Predicts for Worse Survival in Lymphoma Patients Given Allogeneic Peripheral Blood Stem Cells After Non-Myeloablative Conditioning,
Authors: Aurélie Jaspers, Pacome Fosse, Nadia Withofs, Marie Lejeune, Evelyne Willems, Kaoutar Hafraoui, Roland Hustinx, Frederic Baron, Yves Beguin
Journal: Blood (2011)
Effect of the Percent Decrease in Monoclonal Protein with Induction Therapy on the Outcome after Autologous Stem Cell Transplantation in Patients with IgG and IgA Multiple Myeloma.
Authors: Donna E. Reece, Young Trieu, Alida Pokoradi, Wei Xu, Sharon Fung, Christine Chen, Vishal Kukreti, Joseph Mikhael, Suzanne Trudel, A. Keith Stewart
Journal: Blood (2007)
Defining Septic Shock—Reply
Authors: Manu Shankar-Hari, Mervyn Singer
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Comprehensive care programme for patients with chronic obstructive pulmonary disease: a randomised controlled trial
Authors: Fanny W S Ko, N K Cheung, Timothy H Rainer, Christopher Lum, Ivor Wong, David S C Hui
Journal: Thorax (2016)

<h3>Background</h3> There have been no randomised controlled trials that specifically evaluate the effect of a comprehensive programme with multidisciplinary input on patients who have just been discharged from hospital after treatment of acute exacerbation of COPD (AECOPD). The aim of this study was to assess whether a comprehensive care programme would decrease hospital readmissions and length of hospital stay (LOS) for patients with COPD. <h3>Methods</h3> Patients discharged from hospital after an episode of AECOPD were randomised to an intervention group (IG) or usual care group (UG). The IG received a comprehensive, individualised care plan which included education from a respiratory nurse, physiotherapist support for pulmonary rehabilitation, 3-monthly telephone calls by a respiratory nurse over 1 year, and follow-up at a respiratory clinic with a respiratory specialist once every 3 months for 1 year. The UG were managed according to standard practice. The primary outcome was hospital readmission rate at 12 months. <h3>Results</h3> 180 patients were recruited (IG, N=90; UG, N=90; mean±SD age 74.7±8.2 years, 172 (95.6%) men; mean±SD FEV<sub>1</sub> 45.4±16.6% predicted). At 12 months, the adjusted relative risk of readmission was 0.668 (95% CI 0.449 to 0.995, p=0.047) for the IG compared with the UG. At 12 months, the IG had a shorter LOS (4.59±7.16 vs 8.86±10.24 days, p≤0.001), greater improvement in mean Modified Medical Research Council Dyspnoea Scale (−0.1±0.6 vs 0.2±0.6, p=0.003) and St George9s Respiratory Questionnaire score (−6.9±15.3 vs −0.1±13.8, p=0.003) compared with the UG. <h3>Conclusions</h3> A comprehensive COPD programme can reduce hospital readmissions for COPD and LOS, in addition to improving symptoms and quality of life of the patients. <h3>Trial registration number</h3> NCT 01108835, Results.
P0884 : Interferon and ribavirin-free therapy with sofosbuvir and daclatasvir in a real-life cohort of difficult-to-treat HIV/HCV-coinfected patients with and without portal hypertension
Authors: M. Mandorfer, S. Steiner, P. Schwabl, M.C. Aichelburg, K. Grabmeier-Pfistershammer, A. Rieger, M. Trauner, T. Reiberger, M. Peck-Radosavljevic
Journal: Journal of Hepatology (2015)
Abstract LB-017: Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to marked dependence on PRMT5
Authors: Konstantinos Mavrakis, E Robert McDonald, Michael R. Schlabach, Eric Billy, Gregory R. Hoffman, Antoine deWeck, David A. Ruddy, Kavitha Venkatesan, Greg McAllister, Rosalie deBeaumont, Samuel Ho, Yue Liu, Yan Yan-Neale, Guizhi Yang, Fallon Lin, Hong Yin, Hui Gao, David Randal Kipp, Songping Zhao, Joshua T. McNamara, Elizabeth R. Sprague, Young Shin Cho, Justin Gu, Ken Crawford, Vladimir Capka, Kristen Hurov, Jeffrey A. Porter, John Tallarico, Craig Mickanin, Emma Lees, Raymond Pagliarini, Nicholas Keen, Tobias Schmelzle, Francesco Hofmann, Frank Stegmeier, William R. Sellers
Journal: Cancer Research (2016)

Abstract Metabolic genes are increasingly recognized as targets of somatic genetic alteration in human cancer often leading to profound changes in intracellular metabolite concentrations. 5-Methylthioadenosine Phosphorylase (MTAP) is a key enzyme in the methionine salvage pathway that metabolizes methylthioadenosine (MTA) to adenine and methionine. Its chromosomal position proximal to CDKN2A results in frequent collateral homozygous deletion in a wide range of human cancers. By interrogating data from a large scale deep-coverage pooled shRNA screen across 390 cancer cell line models we found that the viability of MTAP null cancer cells is strongly impaired upon shRNA-mediated depletion of the protein arginine methyltransferase PRMT5. In MTAP deleted cells there is marked accumulation of the substrate MTA and surprisingly, we find that MTA is a specific inhibitor of the catalytic activity of PRMT5. In keeping with these data, knockout of MTAP in an MTAP-proficient cell line led to increased MTA levels and rendered them sensitive to PRMT5 depletion. Moreover, reconstitution of MTAP in an MTAP-deficient cell line fully rescued PRMT5 dependence. Collectively, these findings indicate that the collateral loss of MTAP in CDNK2A deleted cancers leads to accumulation of MTA that thereby creates a hypomorphic PRMT5 state that is selectively sensitized towards further PRMT5 inhibition. Citation Format: Konstantinos Mavrakis, E Robert McDonald III, Michael R. Schlabach, Eric Billy, Gregory R. Hoffman, Antoine deWeck, David A. Ruddy, Kavitha Venkatesan, Greg McAllister, Rosalie deBeaumont, Samuel Ho, Yue Liu, Yan Yan-Neale, Guizhi Yang, Fallon Lin, Hong Yin, Hui Gao, David Randal Kipp, Songping Zhao, Joshua T. McNamara, Elizabeth R. Sprague, Young Shin Cho, Justin Gu, Ken Crawford, Vladimir Capka, Kristen Hurov, Jeffrey A. Porter, John Tallarico, Craig Mickanin, Emma Lees, Raymond Pagliarini, Nicholas Keen, Tobias Schmelzle, Francesco Hofmann, Frank Stegmeier, William R. Sellers. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to marked dependence on PRMT5. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr LB-017.
ABCB1 Haplotypes Are Associated With Lower P-Gp Activity and Major Molecular Response But Do Not Affect Imatinib Plasma Levels In Chronic Myeloid Leukemia Patients
Authors: Douglas Vivona, Luciene Terezina Lima, Alice C Rodrigues, Carolina Tosin Bueno, Cristiane M Gaitani, Carlos S Chiattone, Vania T Hungria, Maria de Lourdes L. F. Chauffaille, Elvira Maria Guerra-Shinohara
Journal: Blood (2013)
Intratumoral expression of mature human neutrophil peptides-1 increases the therapeutic effects of chemotherapy in mice.
Authors: Y. Wang
Journal: Journal of Clinical Oncology (2011)

e13517 Background: Human neutrophil peptides (HNP1-3) are expressed within tumors and exhibit extensive cytotoxicity to various tumor cells in vitro. The anti-tumoral mechanisms of HNP1-3 involve in damage on cell membranes and mitochondria. The expression of HNP1-3 within tumors may thus improve the therapeutic effects of chemotherapy. Methods: Here, we aimed to explore the effects of intratumoral expression of mature HNP1 on chemotherapy both in vitro and in mouse 4T1 mammary carcinoma model and human A549 lung xenograft models. HNP1 was introduced into tumor cells using a recombinant plasmid expressing a secretable form of mature HNP1 (pHNP1). Results: Intracellular expression of HNP1 resulted in significant decrease of mitochondrial membrane potential. The significantly increased accumulation of DOX was observed in HNP1-expressing cells. The MTT assay and flow cytometry results revealed that 4T1 cells pre-transfected with pHNP1 were significantly more sensitive to chemotherapeutic drugs. In vivo, the intratumoral expression of HNP1 significantly potentiates the antitumor effect of both Dox and DDP, and resultes in synergistic apoptosis and decreased lung metastases in 4T1 model tumors. Conclusions: These findings indicate that mature HNP1 may function as a potent chemosensitizer for chemotherapeutic improvement in breast and lung cancers. Our study also suggests that the damage on cell membranes and injury of mitochondria mediated by HNP1 may provide a new strategy for reverse of chemotherapy resistance.
Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma.
Authors: Andrea Borghese Apolo, Yusuke Tomita, Min-Jung Lee, Sunmin Lee, Ari Frosch, Seth M. Steinberg, James L. Gulley, Jeffrey Schlom, Donald P Bottaro, Jane B. Trepel
Journal: Journal of Clinical Oncology (2014)

4501 Background: Myeloid-derived suppressor cells (MDSC) and regulatory T cells (Treg) are major components of the immune suppressive tumor microenvironment. Both cell types promote effector T-cell dysfunction and tumor progression. The effect of cabozantinib, a tyrosine kinase inhibitor primarily targeting MET and VEGFR2 on specific immunosuppressive subsets, is unclear. In this study we assess MDSC and Tregs in patients undergoing treatment with cabozantinib and correlate with clinical response to therapy. Methods: Peripheral blood samples were obtained from patients with advanced/refractory metastatic urothelial carcinoma undergoing treatment with cabozantinib under a clinical trial at the National Cancer Institute (NCT01688999). MDSC (CD11b+CD33+CD14-) and Tregs (CD4+CD25hi Foxp3+) were measured in 24 patients at baseline and after 2 cycles of continuous cabozantinib treatment. MDSC and Tregs were further analyzed for CD40 and PD-1, respectively, as suppressive functional markers. Results: Patients with low Tregs at baseline had an improved partial response (PR) rate (p=0.014), progression free survival (PFS) (p=0.059) and overall survival (OS) (p=0.0071). Tregs decreased with cabozantinib treatment (p=0.015). Overall, PD-1 expression in Tregs increased after cabozantinib (p=0.011). However, patients with a PD-1 change below the median showed a strong trend to improved PFS compared to those with increased PD-1 above the median (p=0.035). The percent MDSC did not change with treatment. However, MDSC CD40 expression was increased after cabozantinib treatment compared to baseline (p=0.0005). Though, a decrease in MDSC CD40 expression after treatment was associated with an improved PFS (p=0.020). Conclusions: Treg levels prior to cabozantinib treatment are predictive of therapeutic responsiveness and OS. Changes in Treg PD-1 expression and MDSC CD40 expression may be prognostic markers in patients with advanced/refractory metastatic urothelial carcinoma treated with cabozantinib.
HIV Infection Linked to Injection Use of Oxymorphone in Indiana, 2014–2015
Authors: Philip J. Peters, Pamela Pontones, Karen W. Hoover, Monita R. Patel, Romeo R. Galang, Jessica Shields, Sara J. Blosser, Michael W. Spiller, Brittany Combs, William M. Switzer, Caitlin Conrad, Jessica Gentry, Yury Khudyakov, Dorothy Waterhouse, S. Michele Owen, Erika Chapman, Jeremy C. Roseberry, Veronica McCants, Paul J. Weidle, Dita Broz, Taraz Samandari, Jonathan Mermin, Jennifer Walthall, John T. Brooks, Joan M. Duwve
Journal: New England Journal of Medicine (2016)

In January 2015, a total of 11 new diagnoses of human immunodeficiency virus (HIV) infection were reported in a small community in Indiana. We investigated the extent and cause of the outbreak and implemented control measures.We identified an outbreak-related case as laboratory-confirmed HIV infection newly diagnosed after October 1, 2014, in a person who either resided in Scott County, Indiana, or was named by another case patient as a syringe-sharing or sexual partner. HIV polymerase (pol) sequences from case patients were phylogenetically analyzed, and potential risk factors associated with HIV infection were ascertained.From November 18, 2014, to November 1, 2015, HIV infection was diagnosed in 181 case patients. Most of these patients (87.8%) reported having injected the extended-release formulation of the prescription opioid oxymorphone, and 92.3% were coinfected with hepatitis C virus. Among 159 case patients who had an HIV type 1 pol gene sequence, 157 (98.7%) had sequences that were highly related, as determined by phylogenetic analyses. Contact tracing investigations led to the identification of 536 persons who were named as contacts of case patients; 468 of these contacts (87.3%) were located, assessed for risk, tested for HIV, and, if infected, linked to care. The number of times a contact was named as a syringe-sharing partner by a case patient was significantly associated with the risk of HIV infection (adjusted risk ratio for each time named, 1.9; P<0.001). In response to this outbreak, a public health emergency was declared on March 26, 2015, and a syringe-service program in Indiana was established for the first time.Injection-drug use of extended-release oxymorphone within a network of persons who inject drugs in Indiana led to the introduction and rapid transmission of HIV. (Funded by the state government of Indiana and others.).
Whole Women’s Victory — or Not?
Authors: R. Alta Charo
Journal: New England Journal of Medicine (2016)

Interview with Prof. R. Alta Charo on the implications of the Whole Woman's Health case and likely future anti-abortion strategies. (10:27)Download Facts about women's health won out over fiction in June, when the Supreme Court struck down Texas regulations aimed at closing abortion clinics. Will facts about human development be adequate to overcome fiction in the next front in the abortion wars: fetal pain?
DNA methylation profiling of renal cell carcinomas subtypes to identify epi-clusters linked to cell ontogeny.
Authors: Gabriel G. Malouf, Xiaoping Su, Jianping Zhang, Thai Huu Ho, Yue Lu, Noel J-M Raynal, Jose A. Karam, Pheroze Tamboli, Frederick Allanick, Roger Mouawad, David Khayat, Christopher G. Wood, Jaroslav Jelinek, Nizar M. Tannir
Journal: Journal of Clinical Oncology (2016)

4512 Background: Although genotype-phenotype correlations have been described for different subtypes of renal cell carcinoma (RCC), it is unknown if DNA methylation profiles correlate with morphological or ontology based phenotypes. Here we test the hypothesis that DNA methylation signatures of different RCC can discriminate between putative precursor cells in the nephron. Methods: We performed deep profiling of DNA methylation using Digital Restriction Analysis of DNA Methylation (DREAM) based on next generation sequencing analysis of methylation-specific signatures in diverse histopathological RCC subtypes (n = 22). We furthermore validated our findings in an independent dataset of diverse histopathological RCC subtypes (n = 44) and in The Cancer Genome Atlas Clear Cell (n = 424) and Chromophobe Renal Cell Carcinoma (n = 66) Datasets. Results: Our data provide the first mapping of methylome epi-signature and indicates that RCC subtypes can be grouped into two major epi-clusters: C1 which encompasses clear-cell RCC (n = 4), papillary RCC (n = 5), mucinous and spindle cell carcinomas (n = 2) and translocation RCC (n = 5); C2 which comprises oncocytoma (n = 2) and chromophobe RCC (n = 4). Interestingly, C1 epi-cluster displayed three fold more hypermethylation as compared to C2 epi-cluster. Of note, differentially methylated regions between C1 and C2 epi-clusters occur in gene bodies and intergenic regions, instead of gene promoters. These data was validated in an independent dataset using supervised clustering. Transcriptome analysis of C1 epi-cluster suggests a functional convergence on Polycomb targets, whereas C2 epi-cluster displays DNA methylation defects. Finally, our epigenetic ontogeny signature was associated with worse outcomes of patients with clear-cell RCC, suggesting that cell of origins matters for RCC prediction purposes. Conclusions: Our data defines two epi-clusters that can discriminate between distinct RCC subtypes and for the first time, to our knowledge, define the epigenetic basis for proximal versus distal tubule derived kidney tumors. Genes defining ontogeny epi-signature might be used in the future to predict patients outcome.